factually
Index/Topics/Tau PET

Tau PET

Using tau PET to refine prognosis beyond amyloid magnitude

Fact-Checks

2 results
Feb 3, 2026

How should clinicians integrate Centiloid values with tau PET and CSF biomarkers to estimate individual dementia risk?

Clinicians should use (CL) values as a standardized continuous measure of brain and interpret them alongside and CSF biomarkers in a staged, complementary framework: low CLs can identify early amyloid...

Feb 1, 2026

How do baseline tau PET levels modify the effect of amyloid‑lowering antibodies on clinical decline?

Baseline measured by strongly modifies how much clinical benefit patients derive from amyloid‑lowering antibodies: lower neocortical tau at baseline associates with larger slowing of cognitive decline...